TROP2 Is Uniformly Expressed in Primary Prostate Cancer but Frequently Reduced in Recurrent Disease
{{output}}
Background: TROP2 (TACSTD2) is a therapeutic target of antibody-drug conjugates and is broadly expressed in epithelial malignancies. Data on TROP2 protein expression in large, clinically annotated prostate cancer cohorts, particularly in recurrent disease, rem... ...
